Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
Status: Active
Protocol Title: URCC-18007
This phase III trial studies how well bupropion works in reducing cancer related fatigue in stage I-III breast cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in breast cancer survivors.
https://www.clinicaltrials.gov/ct2/show/NCT03996265
High Risk Breast Cancer
Status: On Hold
Protocol Title: A211102
Testing for Atypia in Random Perareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbigunide Hydorchloride) Chemoprevention versus Placebo Control in Premenopausal Women.
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Status: Active
Protocol Title: EA1151
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
https://www.clinicaltrials.gov/ct2/show/NCT03233191
Breast Cancer (Adjuvant)
Status: Active
Protocol Title: A011401
Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Breast Cancer (Adjuvant)
Status: Active
Protocol Title: A011502
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial.
Breast Cancer (Triple Negative)
Status: Active
Protocol Title: ECOG EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast cancer following Neoadjuvant Chemotherapy
Breast Cancer (Triple Negative)
Status: Active
Protocol Title: NRG BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Metastatic Triple Negative Breast Cancer
Status: Active
Protocol Title: NRG BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Breast Cancer (Metastic HER2+)
Status: Active
Protocol Title: Daiichi Sankyo, Inc/ DS8201-301
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibiody drug conjugate, versus treatment of investigator's choice for HER2-positvie, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Status: Active
Protocol Title: ALCHEMIST (A081801)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
https://www.clinicaltrials.gov/ct2/show/NCT04267848?term=A081801&draw=2&rank=1
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Status: Active
Protocol Title: A221805
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
https://www.clinicaltrials.gov/ct2/show/NCT04137107
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Status: Active
Protocol Title: NRG-GI005
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help doctors find out which treatment combination is better at prolonging life in older patients with metastatic pancreatic cancer.
https://www.clinicaltrials.gov/ct2/show/NCT04233866
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
Status: Active
Protocol Title: EA2186
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
https://www.clinicaltrials.gov/ct2/show/NCT04068103
Lung (Adjuvant)-NSLC, tissue study for ALK or EGFR
Status: Active
Protocol Title: ALCHEMIST (A151216)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Lung (Adjuvant)-NSCLC if ALK + for A151216 study
Status: Active
Protocol Title: ALCHEMIST (E4512)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.
Lung (Adjuvant)-NSCLC, State IB-IIIA,If EGFR + in A151216 study
Status: Active
Protocol Title: ALCHEMIST (A081105)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Status: Active
Protocol Title: A222004
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
https://www.clinicaltrials.gov/ct2/show/NCT04939090
Ovarian (Stage II or IV)
Status: Active
Protocol Title: NRG GY005
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Cervical Cancer (Locally Advanced)
Status: Coming June/July 2020
Protocol Title: MK3475-A18/ ENGOT-cx11
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy with or without Pembrolizumab For The Treatment of High-Risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11)
Head/Neck Cancer
Status: Coming June/July 2020
Protocol Title: EA3161
A Phase II/III Randomized Study of maintenance Nivolumab versus Obversation In Patient with Locally Advanced, Intermediate Risk HPV positive OPCA (oral pharangeal cancer)
High Risk Breast Cancer
Status: Coming June/July 2020
Protocol Title: Caris
Biorespoistory-Prep-Breast Biopsy